
This clinical trial was performed to study the effects of zzso zzso administered zzso human zzso zzso zzso at escalating doses zzso zzso and 450 zzso administered as an IV zzso injection, twice weekly, for 6, 4, and 4 weeks, zzso in five patients with zzso zzso zzso zzso zzso and bone zzso involvement and one patient with multiple myeloma zzso All patients were anemic due to underlying zzso None of the patients had a history of zzso zzso zzso zzso or other disorders causing anemia in addition to bone zzso zzso zzso zzso EPO serum levels were significantly increased in all patients zzso to 202 zzso Five patients (one zzso four zzso zzso zzso zzso showed a dramatic increase of zzso zzso zzso zzso and zzso count becoming obvious on the second EPO dose zzso zzso zzso serum values, which were high mostly due to zzso were significantly reduced in responding zzso zzso of one patient with extensive zzso mixed zzso NHL did not respond to EPO zzso zzso zzso count increase zzso than zzso above starting zzso during and following EPO therapy was observed in one patient with zzso zzso events due to EPO therapy have not been zzso These findings point out a previously zzso capacity of EPO given at zzso doses to stimulate zzso in patients with anemia due to bone zzso zzso by zzso zzso in spite of enhanced zzso EPO zzso 

